echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Amgen 2021Q1: Strong growth of biosimilar drugs AMG510 approval ends...

    Amgen 2021Q1: Strong growth of biosimilar drugs AMG510 approval ends...

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 27, Amgen announced its results for the first quarter of 2021.


    Although product sales have fallen by 5% year-on-year, there are still some products showing double-digit sales growth, including Repatha (Iloyuumab), Prolia (desulumab) and the biosimilar MVASI (bevacizumab) Monoclonal antibody) and KANJINTI (trastuzumab).


    Although sales of Enbrel (etanercept), an autoimmune disease treatment drug for rheumatoid arthritis, fell 20% from the first quarter of last year, it was still Amgen’s highest-revenue product, reaching US$924 million.


    Sales of the new blood lipid-lowering drug REPATHA (Iloyuumab) increased by 25% year-on-year to US$286 million, mainly driven by a 36% increase in sales.


    The most eye-catching focus of Amgen should be the KRAS inhibitor LUMAKRAS™ (sotorasib) every move.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.